For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
Scope of the Report:
According to the research, the most potential market in the main countries of circulating tumor cells (CTCs) and cancer stem cells (CSCs) industry is China, determined by the rising level of medical care. Besides, South America, Asia-Pacific should also be focused by the investors. They are the potential consumers of circulating tumor cells (CTCs) and cancer stem cells (CSCs).
The CellSearch test is the only FDA-approved test for CTC assessment. For the moment, the products are not comprehensive, and technologies are not stable.
Morbidity and mortality rate of cancer is rising at a faster speed worldwide and thus prevention of cancer and cancer treatment is grabbing attention of cancer researchers globally. Stem cells and cell therapy have shown significant potential to treat cancer effectively.
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market is valued at 6420 million USD in 2018 and is expected to reach 21700 million USD by the end of 2024, growing at a CAGR of 22.5% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market by product type and applications/end industries.
Market Segment by Companies, this report covers
- Janssen
- Qiagen
- Advanced Cell Diagnostics
- ApoCell
- Biofluidica
- Clearbridge Biomedics
- CytoTrack
- Celsee
- Fluxion
- Gilupi
- Cynvenio
- On-chip
- YZY Bio
- BioView
- Fluidigm
- Ikonisys
- AdnaGen
- IVDiagnostics
- Miltenyi Biotec
- ScreenCell
- Silicon Biosystems
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- CellSearch
- Others
Market Segment by Applications, can be divided into
- Breast Cancer Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Colorectal Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Other Cancers Diagnosis and Treatment